{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:48:21Z","timestamp":1791146901235,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.3816\/cbc.2007.s.001","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:04:54Z","timestamp":1221167094000},"page":"S7-S13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S1","title":["Biology of Bone Metastases: Causes and Consequences"],"prefix":"10.3816","volume":"7","author":[{"given":"Harold A.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"von Reyn Cream","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2007.s.001_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CBC.2007.s.001_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11864-005-0023-0","article-title":"Management of bone metastases in breast cancer","volume":"6","author":"Lipton","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"issue":"4 suppl 11","key":"10.3816\/CBC.2007.s.001_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0093-7754(01)90235-0","article-title":"Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease","volume":"28","author":"Hillner","year":"2001","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib5","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.2005.03.8802","article-title":"Genes associated with breast cancer metastatic to bone","volume":"24","author":"Smid","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib6","first-page":"18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr Rev"},{"key":"10.3816\/CBC.2007.s.001_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone matastases","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.3816\/CBC.2007.s.001_bib9","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.3816\/CBC.2005.s.004","article-title":"Molecular mechanisms of breast cancer metastases to bone","volume":"5","author":"Guise","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib10","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","article-title":"Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway","volume":"65","author":"Bendre","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2007.s.001_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","article-title":"Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy","volume":"10","author":"Kozlow","year":"2005","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"suppl","key":"10.3816\/CBC.2007.s.001_bib12","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/01.blo.0000093055.96273.69","article-title":"Transforming growth factor-beta in osteolytic breast cancer bone metastases","volume":"415","author":"Guise","year":"2003","journal-title":"Clin Orthop Relat Res"},{"issue":"4 suppl 11","key":"10.3816\/CBC.2007.s.001_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0093-7754(01)90225-8","article-title":"Preclinical models of bone metastases","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib14","first-page":"308","article-title":"Tumor-bone cellular interactions in skeletal metastases","volume":"4","author":"Chirgwin","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.3816\/CBC.2007.s.001_bib15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancerinduced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"issue":"suppl","key":"10.3816\/CBC.2007.s.001_bib16","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/01.blo.0000093047.96273.4e","article-title":"Mechanisms of osteoblastic metastases: role of endothelin-1","volume":"415","author":"Mohammad","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.3816\/CBC.2007.s.001_bib17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2007.s.001_bib19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, duoble-blind, multicenter comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib20","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.3816\/CBC.2007.s.001_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bishosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Invest"},{"key":"10.3816\/CBC.2007.s.001_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"key":"10.3816\/CBC.2007.s.001_bib23","first-page":"15","article-title":"Pathophysiology of bone pain","volume":"3","author":"Sabino","year":"2005","journal-title":"J Support Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib24","first-page":"123","article-title":"The management of hypercalcemia of malignancy","volume":"3","author":"Harvey","year":"1995","journal-title":"Support Care Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.7-6-481","article-title":"The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy","volume":"7","author":"Major","year":"2002","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2007.s.001_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib27","doi-asserted-by":"crossref","first-page":"S6397","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2007.s.001_bib28","first-page":"260","article-title":"Fractures negatively affect survival in patients with bone metastases from breast cancer","volume":"94","author":"Hei","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2007.s.001_bib29","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0305-7372(06)80005-8","article-title":"Biochemical bone markers in breast cancer","volume":"32","author":"Lipton","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CBC.2007.s.001_bib31","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1097\/01.blo0000092979.12414.54","article-title":"Biochemical markers and skeletal l metastases","volume":"415","author":"Demers","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.3816\/CBC.2007.s.001_bib32","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.radonc.2005.03.003","article-title":"Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review","volume":"75","author":"Bauman","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10147-005-0478-9","article-title":"Surgical treatment of bone metastasis: indications and outcomes","volume":"10","author":"Manabe","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"10.3816\/CBC.2007.s.001_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharm Exp Ther"},{"key":"10.3816\/CBC.2007.s.001_bib37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2007.s.001_bib38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib39","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib40","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biologic receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.s.001_bib41","first-page":"6S","article-title":"Phase II trial of denosumab in breast cancer with bone metastases","volume":"24","author":"Lipton","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.001_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2007.s.001_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.3816\/CBC.2007.s.001_bib45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. ATAC Trialists' Group","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2007.s.001_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2007.s.001_bib47","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2007.s.001_bib48","first-page":"21","article-title":"The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy","volume":"18","author":"Smith","year":"2004","journal-title":"Oncology"},{"key":"10.3816\/CBC.2007.s.001_bib49","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"key":"10.3816\/CBC.2007.s.001_bib50","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/07357900600633759","article-title":"Management of bone loss induced by aromatase inhibitors","volume":"24","author":"Gnant","year":"2006","journal-title":"Cancer Inv"},{"key":"10.3816\/CBC.2007.s.001_bib51","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","article-title":"Management of cancer treatment induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update","volume":"33","author":"Brufsky","year":"2006","journal-title":"Semin Oncol"},{"issue":"6 suppl 12","key":"10.3816\/CBC.2007.s.001_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.seminoncol.2004.09.023","article-title":"Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy","volume":"31","author":"Harvey","year":"2004","journal-title":"Semin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091170800X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091170800X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:56Z","timestamp":1761513056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091170800X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":52,"alternative-id":["S152682091170800X"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2007.s.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biology of Bone Metastases: Causes and Consequences","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2007.s.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}